CSIR, Laxai Life Sciences get DCGI nod for clinical trials of Colchicine on COVID-19 patients
Enrolment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks.
June 15, 2021
by expresspharma
CSIR-IICT, Lee Pharma sign agreement to produce 2-D
Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam, Andhra Pradesh.
June 10, 2021
by expresspharma
NMPB and CSIR-NBRI sign MoU for promoting cultivation and production of medicinal plants
Through this collaboration, NMPB will support CSIR-NBRI in carrying out the potential medicinal plant species with high commercial value for germplasm collection/conservation and establishment of nursery and seed banks/gene banks.
June 8, 2021
by expresspharma
CSIR and Laxai Life Sciences begin phase II trial of niclosamide drug to treat COVID-19
Niclosamide has been extensively used in the past for treating tapeworm infection in adults as well as children.
June 8, 2021
by expresspharma
Scientific community rose to occasion when COVID-19 hit country: Vardhan
The three-day event from March 1-3 will showcase the strength and opportunities of the India's biotechnology sector at national level and to the global community.
March 2, 2021
by expresspharma
Expect to commercialise vaccine facility by April-May 2021: Aurobindo Pharma
It is investing around Rs 275 crores on the facility to produce vaccines for the treatment of various viral diseases including COVID-19.
December 1, 2020
by expresspharma
CSIR announces Shanti Swarup Bhatnagar Prize 2020 to 14 scientists
The scientists work in renowned national research and academic institutions across the country.
September 28, 2020
by expresspharma
CSIR and Mylan in partnership to develop therapeutic options for COVID–19 management
The application for the clinical trials has been submitted to DCGI for regulatory approval.
September 24, 2020
by expresspharma
CSIR and Aurobindo Pharma to collaborate for COVID-19 vaccine development
DBT is also supporting Aurobindo Pharma’s COVID-19 vaccine development through its wholly-owned US subsidiary Auro Vaccines, under the National Biopharma Mission.
September 16, 2020
by expresspharma
CSIR seeks regulatory nod for clinical trials using combination of antivirals and HDTs against COVID-19
It is to determine safety and efficacy of three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.
July 8, 2020
by expresspharma
CDRI gets approval for Phase III trial of Umifenovir to treat Covid-19
Central Drug Research Institute (CDRI), a constituent lab of India-based Council of Scientific and Industrial Research (CSIR), has secured approval for carrying out Phase III trial for the use of Umifenovir in the treatment of Covid-19.
June 22, 2020
by pharmaceutical-technology
CSIR’s anti-cancer drug IIIM-290 goes into clinical trial
The clinical trial aims to assess safety, tolerability and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients.
June 9, 2020
by expresspharma